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Summary 
Background 
Hair and scalp problems are common. Unfortunately, many uncertainties exist around the 
most effective management and treatments strategies for these disorders. 
Objectives 
To identify uncertainties in hair loss management, prevention, diagnosis and treatment that 
are important to both people with hair loss and healthcare professionals.  
Methods 
A hair loss priority setting partnership was established between patients, their carers and 
relatives, and healthcare professionals to identify the most important uncertainties in hair 
loss. The methodology of the James Lind Alliance was followed to ensure a balanced, 
inclusive and transparent process.   
Results 
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In total 2747 treatment uncertainties were submitted by 912 participants; following 
exclusions 884 uncertainties relating to hair loss (excluding alopecia areata) were analyzed. 
Questions were combined into “indicative uncertainties” following a structured format. A 
series of ranking exercises further reduced this list to a top 25 that was taken to a final 
prioritization workshop where the top 10 priorities were agreed. 
Conclusions 
We present the top 10 research priorities for hair loss (excluding alopecia areata) to guide 
researchers and funding bodies to support studies important to both patients and clinicians. 
 
What’s already known about the topic? 
• Many uncertainties exist around the management and treatment of hair loss 
What does the study add? 
• We present the top 10 uncertainties in hair loss management, prevention, diagnosis and 
treatment that are important to patients, their carers and healthcare professionals 
• These prioritized research uncertainties can be used to guide researchers and funding 
bodies when deciding to invest in hair loss research studies 
 
 
Funding:  
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Conflicts of interest: None declared. 
 
Introduction 
Hair and scalp problems are common in the general population with an overall prevalence of 
8.2% reported in one UK study 1. Various conditions can result in hair loss and may present 
as increased hair shedding (telogen effluvium) 2, hair thinning (in a pattern or diffusely) or 
patchy to complete hair loss (e.g. alopecia areata, primary cicatricial alopecias) 3-5. In some 
conditions the hair may regrow, in others the alopecia is permanent. Frequently overlooked is 
the psychological impact of hair loss on an individual. The visible nature of hair loss and fear 
of progression may lead to low self-esteem, anxiety and depression 6. Many uncertainties 
exist about the most effective ways to manage these different hair loss disorders. Our limited 
understanding of disease pathogenesis and natural history, with the relative lack of validated 
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severity scales for each condition is reflected in the poor quality of evidence for treatments 
and interventions currently available.  
 
The James Lind Alliance (JLA) is a project funded by the National Institute of Health 
Research (NIHR) with support from the Medical Research Council. The aim of the JLA is to 
provide infrastructure and support to patients and clinicians working together to identify the 
most important treatment uncertainties affecting their particular interest, in order to stimulate 
and prioritize future research in that area. The Priority Setting Partnership (PSP) presented 
here was proposed by the British Hair and Nail Society (BHNS) to address treatment 
uncertainties highlighted by systematic reviews, treatment guidelines and clinical experience, 
for all types of hair loss. Working with the JLA and funded by the hair loss charity Alopecia 
UK, the Hair Loss PSP presents priorities for UK hair research in a bid to raise the profile of 
hair loss disorders and to open funding streams to address these important research questions. 
 
The objectives of the Hair Loss PSP were (1) to work with people with hair loss, their 
partners / parents / carers and healthcare providers to identify uncertainties about hair loss 
management, prevention, diagnosis and treatment, (2) survey the research literature to 
identify uncertainties and research recommendations, (3) agree by consensus a prioritized list 
of those uncertainties, (4) translate these prioritized uncertainties into research questions that 
can be tested, (5) publicize the results of the PSP and process of obtaining them, and (6) take 
the results to research commissioning bodies to be considered for funding. All identified 
uncertainties from this process will be added to the UK Database of Uncertainties about the 
Effects of Treatments (UK-DUETs) (www.library.nhs.uk/duets). 
 
In contrast to previous dermatology PSPs 7-9, the challenge of this process was how to 
represent the broad range and incidence of conditions that manifest with hair loss. We 
initially opened the PSP to address all types of hair loss within the same process. However, 
analysis of the initial survey revealed that around half of the responses related to alopecia 
areata (AA; including alopecia totalis / universalis). Therefore, the Steering Group (SG) felt 
it was appropriate to separate the analysis at this point into two separate PSP processes that 
would run in parallel yet remain under supervision of the same SG membership. The 
rationale for this change was to prevent one condition dominating the process whilst 
maximizing identification of important uncertainties across all conditions studied. The 
alopecia areata PSP outcomes are reported separately [ref to be inserted]. 
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Methods 
Following the principles and guidelines set by the JLA, the hair loss PSP adhered to a pre-
determined protocol to ensure transparency and inclusivity of all parties within the process 
(www.jla.nihr.ac.uk/priority-setting-partnerships/hair-loss). The SG was established in March 
2014 and comprised four people with hair loss representing various patient support groups, 
four Dermatologists, a Psychologist, a registered Trichologist and a General Practitioner 
(GP). A JLA representative provided independent oversight of the PSP and chaired the SG. 
All potential conflicts of interest were declared prospectively. The five stages of the PSP 
process are outlined below and summarized in Figure 1. 
 
Stage 1 – Identification and invitation of potential partners 
Key stakeholders were identified through a process of consultation and peer knowledge, 
building on SG members’ networks and existing JLA affiliates. Special consideration was 
given to how all the different types of hair loss would be represented in this process. Thus, a 
broad range of stakeholder groups were approached and invited to become partners in the 
PSP process.    
 
In addition to the BHNS, JLA and Alopecia UK, the following partners engaged in the hair 
loss PSP: The British Association of Dermatologists, UK Dermatology Clinical Trials 
Network (UK DCTN), The Institute of Trichologists, British Dermatology Nursing Group, 
Skin Conditions Campaign Scotland, Alopecia Help and Advice (Scotland), Scottish 
Alopecia Support Group, My New Hair, British Association of Skin Camouflage, Changing 
Faces, European Hair Research Society, “Look Good, Feel Better”, British Association of 
Hair Restoration Surgery and the Cicatricial Alopecia Research Foundation. 
 
Stage 2 – Invitation to submit uncertainties 
Survey 1 took place from 8th September 2014 – 31st October 2014 and was advertised as open 
to anyone residing in the UK. Geographical analysis of respondents who provided location 
details showed that 2% (14/630) did not reside in the UK. The initial invitation to submit 
uncertainties involved an online survey (Survey Monkey™) accessed through the Alopecia 
UK website (www.alopeciaonline.org.uk). In addition, paper surveys were available on 
request and were also distributed at key events. Through engagement with the various partner 
organizations, local advertisement and via social media, a range of people with different hair 
loss conditions, their carers and relatives, and healthcare professions were targeted.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Uncertainties were invited by asking the following question: “Do you have questions about 
prevention, diagnosis or treatment of hair loss that need to be answered by research?”. 
Participants were permitted to submit as many or as few questions as they wished, and these 
could relate to one or more hair loss conditions. The survey questionnaire was designed to 
link the research question with hair loss type as it was anticipated that questions relating to 
more than one condition would be generated by an individual, with healthcare professionals 
in particular anticipated to submit uncertainties relating to different disease types. The survey 
contained a participant information sheet to provide background to the process and survey 
text was designed to be easy to understand and provide all the relevant information for self-
completion. Submitting the completed survey was considered as consent to participate in the 
PSP process and publish the (anonymized) uncertainties on UK-DUETs. 
 
Stage 3 - Collation 
The aim of this stage was to review all the submitted questions, exclude questions outside the 
remit of the PSP and generate “indicative uncertainties” (i.e. a collation of similar questions 
into one clear, understandable question presented in a standard format). Non-questions (e.g. 
statements or comments) and questions not directly relating to a hair loss disorder were 
excluded. Questions that could be resolved with reference to existing research evidence (so 
called "unknown knowns") were identified from existing sources of information, in particular 
systematic reviews, evidence based guidelines and prospective trial registers. Exclusion of 
questions or comments outside of the remit of the Hair Loss PSP were made by consensus 
within the SG. Uncertainties which were not adequately addressed by previous research were 
collated and entered into a hair loss section within UK DUETs (www.library.nhs.uk/duets). 
 
Stage 4 – Ranking of treatment uncertainties 
The aim of this stage was to generate a short-list of indicative uncertainties deemed by both 
people with hair loss and healthcare professionals to be important. To reduce the large 
number of indicative uncertainties generated in stage 3 to a reasonable number for ranking, 
an “interim list” was created using criteria agreed by the SG. These criteria were designed to 
identify which questions were asked most frequently, with inclusion of questions asked by 
more than one person and questions asked by both people with hair loss and healthcare 
professions independently. The SG also identified 5 questions that were asked by only one 
person that were felt warranted inclusion and also a further 2 questions written by the steering 
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group to express the concerns illustrated in the free text statements of participant personal 
experience. This process generated a list of 56 questions to go forward to the second survey.  
 
The second online ranking survey ran from 22nd September 2015 to 4th October 2015 and was 
completed by previous participants to further refine the interim list into a short-list of 25 
uncertainties to take to the final workshop. Participants were invited to choose up to ten 
uncertainties from the interim list but were not asked to prioritise them. The responses 
obtained were used to rank the uncertainties by number of votes. The priorities of the 
different groups of responders were listed separately and compared. 
 
Stage 5- Final workshop 
The final workshop took place on 7th November 2015 at Willan House in London. The aim of 
this stage was to prioritize through consensus the most important uncertainties relating to the 
management, prevention, diagnosis and treatment of hair loss. This was carried out by 
eligible members of the SG and the wider partnership that represents people with hair loss 
and healthcare professional (including Dermatologists, Trichologists, GPs, Hair Transplant 
Surgeons and a Psychologist). The process was facilitated by the JLA to ensure fairness, 
transparency and accountability. Using nominal group technique, consensus was achieved 
through a series of ranking and plenary sessions, eventually generating the top ten research 
priorities.  Those attending the priority setting workshop were asked to complete a 
declaration of interests, including disclosure of relationships with for-profit organizations.   
 
Results 
The initial survey was completed by 912 participants generating 2747 responses, with 83% of 
submissions being completed by people with hair loss, carers or relatives and 13% by 
healthcare professionals or hair loss organizations (Figure 2). After removal of non-questions 
and those deemed “out of scope”, 1823 uncertainties remained. After exclusion of 
uncertainties relating to AA (reported separately), 884 uncertainties related to all other types 
of hair loss remained.    
 
Eleven of the 884 submitted uncertainties could be answered from available evidence and so 
were excluded. Indicative uncertainties were generated by combining similar questions and 
standardized using “PICO” (Population Intervention Comparator Outcome) formatting. In 
addition to specific disease related questions, “generic” uncertainties relevant to all types of 
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hair loss were also identified. Where appropriate, similar questions submitted for a number of 
conditions were combined into an indicative question relevant to “all hair loss types”. This 
process generated an interim list of 201 uncertainties that was further reduced by ranking 
questions based on the number of times submitted, with priority given to those questions 
submitted by both people with hair loss and healthcare professionals. The top 56 uncertainties 
were taken forward to the second ranking survey and of these the top 25 uncertainties were 
then taken to the final workshop.  
Of note, the additional 7 questions identified by the steering group at interim ranking phase 
were not prioritized in the second survey for the final workshop, with the exception of the 
question How aware are GPs of the early signs of hair loss and their management?”, ranked 
number 7, which seemed to represent the large number of free text comments related to 
diagnosis in General Practice in the initial survey. 
 
Participants at the final workshop were divided into three groups, each with an independent 
facilitator and including similar numbers of people with hair loss, healthcare professionals 
and representatives of partner organisations. A series of group and plenary sessions used 
discussion to select the “Top 10” research uncertainties by consensus (Table 1). 
 
Independent facilitators, with prior experience of PSP workshops, provided by the JLA 
ensured that the discussions were not influenced heavily or steered by any particular 
individual or group. Participants signed a declaration of interest form prior to participation in 
the workshop to ensure no personal or commercial interests influenced the final prioritization 
process. 
 
Discussion 
Here we present an overview of this PSP that has demonstrated a number of uncertainties 
relating to the management, prevention, diagnosis and treatment of hair loss. By adhering to 
the JLA ethos of inclusivity and transparency, and using a combination of online surveys and 
face-to-face workshops, we can feel confident that the outcomes generated here accurately 
reflects the consensus view of both people with hair loss and healthcare professionals in 
determining future priorities for research.  
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Feedback from participants in the final workshop revealed that the opportunity to discuss the 
questions allowed different viewpoints to be aired, identified positions that they had not 
previously considered and lead to a more balanced appraisal of the priorities. Thus, the final 
top 10 did not exactly reflect the ranking (performed independently) from the second survey. 
Discussion on position of ranking was frequently influenced by the other questions presented, 
with certain questions relegated in priority if they were deemed to be covered by other 
uncertainties more highly ranked in the process.  Although deliverability of the research was 
considered in appraising each question, it was acknowledged that the questions broadly 
represented a theme for research that would require refinement before being developed into a 
completed research question.  
 
The top 10 uncertainties are open and broad but reflect the true wording of submissions from 
participants. Creation of focused research questions from the themes identified is a later-stage 
process and these specific research questions will then need to define a population, 
intervention, comparator and outcome and take into account feasibility of such trials.  We can 
be confident that the broad theme of any subsequent research, and associated funding, will 
then follow the priorities identified here and not a separate research track with less impact for 
stakeholders and participants. 
 
Interestingly, a significant proportion of the originally submitted questions did not represent 
an uncertainty at all, but reflected a lack of information around treatment options and service 
provision. Recurring themes included availability of services, treatment strategies, wig 
provision and the low priority given to hair loss in the NHS. Striking was the frequency of 
comments relating to experiences of patients accessing medical services, particularly seeing 
GPs, with many describing a perceived lack of knowledge, reluctance to refer and in some 
cases a lack of compassion when dealing with their distressing problem. Thus, a greater 
awareness and education of GPs / healthcare professionals around hair loss was suggested to 
highlight and address the (openly acknowledged) inadequate dermatology training currently 
received in the UK by many medical students and GP trainees in the field of hair loss. .     
 
Some problems were encountered during the process, mainly around data handling and the 
large number of uncertainties originally submitted (2747 questions). By necessity a “Data 
team” was set up to process these results. However, some inconsistency in taxonomy 
allocation to categorize questions occurred that may have been overcome by just one or two 
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people only handling the results, although this would have significantly prolonged the 
process in time and costs. Another area of difficulty was around engagement of key 
stakeholders. In general smaller and specialized organizations were keen to become partners 
in the process. However, some larger organizations were reluctant to commit to partnership 
but agreed to advertise the PSP to their members, whereas other groups refused to engage 
completely. These decisions appeared to relate to the inability of such large organizations to 
commit to these types of projects for which they are frequently approached to support. As the 
number of PSPs in all fields are likely to increase, with many groups anticipated to want 
engagement with similar stakeholders each time it was felt by the SG that the JLA should 
consider setting up a higher level agreement with the main stakeholder groups (particularly 
the Royal Colleges and Specialist Associations) to provide a minimum level of commitment 
for all future JLA-supported PSP processes. 
 
We present an overview of the hair loss PSP process, including pitfalls encountered along the 
way. By presenting the top 10 uncertainties in hair loss (excluding AA) identified as 
important by both patients and clinicians we hope to raise awareness of these disorders and 
influence research priorities in the future. The outcomes will be put forward to researchers 
and funding bodies with the ultimate aim of securing meaningful research funds to address 
these important issues. 
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Figure legends 
 
Figure 1- Overview of the Hair Loss Priority Setting Partnership process  
 
Figure 2- Division of participants of initial survey by category (n= 912)  
 
Table 1- Top 10 research uncertainties for hair loss disorders (excluding alopecia areata) 
prioritized by consensus. 
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Table 1- Top 10 research uncertainties for hair loss disorders (excluding alopecia areata) 
prioritized by consensus. 
 
 
Rank  Uncertainty  
1  What is the most effective treatment for Frontal fibrosing alopecia? 
2  What are the causes of Frontal fibrosing alopecia? For example- dietary, genetic, 
autoimmune, skin care products, medications, hormonal, environmental, 
vaccination, infection.  
3  What are the causes of female pattern hair loss? For example- genetic, hormonal 
and childbirth, autoimmune, dietary, other medical conditions, 
environmental factors.  
4  In all types of hair loss, are psychological therapies effective in improving patient 
outcomes?  
5  In all types of hair loss, what outcome measures should be used to assess severity 
of hair loss, progression and impact on the individual?  
6  Is spironolactone helpful in managing female pattern hair loss?  
7  In all types of hair loss, does raising ferritin levels/replacing iron improve hair 
growth? And what is the optimal level of ferritin?  
8  What is the most effective treatment for Lichen planopilaris?  
9  In all types of hair loss, do certain diets or nutritional supplements (for example 
vitamin D) prevent or improve hair loss?  
10  In female pattern hair loss, does hormone replacement therapy (HRT) halt 
progression of the hair loss compared to placebo?  
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Stage 1: Identification and Invitation of Potential Partners 
Stage 2: Invitation to Submit Uncertainties (Initial survey)
912 responders with 2747 responses
Stage 3: Collation
884 uncertainties for hair loss disorders (excluding alopecia areata)
Stage 4: Ranking of Treatment Uncertainties
Stage 5: Final Workshop
 
 
 
 
Figure 2- Division of participants in initial survey by category (n= 912)
 
